

CMV-TCIP Directed Letemovir Prophylaxis After Allo-SCT

NCT06453460

Status	RECRUITING
Phase	Phase 2
Sponsor	University of California, Irvine
Enrollment	50 participants

Key Eligibility Criteria

Inclusion (14)

- e 18 years of age on the day of signing informed consent.
- Karnofsky performance $\geq 70\%$
- Have documented seropositivity for CMV (either donor or recipient CMV IgG seropositivity) before AHCT.
- Eligible for AHCT from an HLA-matched related, matched unrelated, mismatched unrelated or haploidentical donor using either bone marrow or peripheral blood stem cells.
- Have undetectable CMV DNA from a plasma sample collected within 5 days prior to enrollment.

... and 9 more (see full listing online)

Exclusion (12)

- Has a history of CMV end-organ disease or CS-CMV_i within 6 months prior to enrollment.
- Received within 7 days prior to screening or plans to receive during the study any of the following:
 - Ganciclovir
 - Valganciclovir
 - Foscarnet

... and 7 more (see full listing online)

Locations (1 total)

Chao Family Comprehensive Cancer Center, University of California Irvine, Orange, California, United States